The promising prospect of the pharmaceutical industry has triggered a wave of mergers and acquisitions in China, and the amount and quantity of mergers and acquisitions have hit record highs. Because of their optimism about the development of domestic pharmaceutical industry, China enterprises are also enthusiastic about M&A in overseas markets.
According to the incomplete statistics of the published Report on Deep Investigation and Investment Strategic Planning of China Pharmaceutical Industry, in 20 16 years, there were more than 400 mergers and acquisitions in the field of medicine and health, with the amount exceeding180 billion yuan. It is expected that the tide of mergers and acquisitions will continue this year, and mergers and acquisitions in various segments will remain highly active.
According to the current trend, M&A in the pharmaceutical industry will continue and slow down relatively until a new market structure is basically formed in the future. After the formation of the new pattern, the pharmaceutical industry will also return to medium and high-speed development.
Generally speaking, with the aging of society, the deepening of the reform of medicine separation and the loosening of the policy of medical e-commerce, the prospects of the pharmaceutical industry are still promising. In the new market environment, pharmaceutical enterprises should seek new sales channels, increase the integration with the Internet, reduce the cost of circulation links and increase their own profits.